CorMedix Inc stock performance trend indicates that the stock price has rallied 1.69% in the past 12 Weeks but analyzing the 6 month chart of the stock, the price of the stock has managed to drop negative and it has dropped down to -28.57% . Looking at the past 52 week period, the stock price is down -29.13% . Relative price strength is a important factor used by wealth management firms while investing in stocks since the indicator compares the stock performance with the overall market. The relative price strength of CorMedix Inc has a negative value of -60.29 compared to overall market performance.CorMedix, Inc. is having a Relative Strength Index of 34.56 which indicates the stock is not yet over sold or over bought based on the technical indicators.
CorMedix Inc (NYSEMKT:CRMD) has tumbled 15.09% during the past week and has dropped 20.71% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 15.3%. CorMedix Inc (NYSEMKT:CRMD) has underperformed the index by 21.61% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
For the current week, the company shares have a recommendation consensus of Buy. CorMedix Inc (NYSEMKT:CRMD) stock ended Friday session in the red zone in a volatile trading. The stock closed down 0.27 points or 13.04% at $1.8 with 1,599,101 shares getting traded. Post opening the session at $1.73, the shares hit an intraday low of $1.44 and an intraday high of $1.89 and the price was in this range throughout the day. The company has a market cap of $73 million and the number of outstanding shares has been calculated to be 40,425,739 shares. The 52-week high of CorMedix Inc (NYSEMKT:CRMD) is $4.54 and the 52-week low is $1.35.
Company has reported several Insider transactions to the SEC, on Mar 1, 2017, Cora M Tellez (director) purchased 1,540 shares at 2.10 per share price.On Feb 8, 2017, Antony Pfaffle (Chief Scientific Officer) sold 10,000 shares at 2.00 per share price.On Dec 13, 2016, Khoso Baluch (CEO) purchased 10,000 shares at 1.77 per share price.
CorMedix Inc. is a development-stage pharmaceutical company that seeks to in-license, develop and commercialize therapeutic products for the treatment of cardiac and renal dysfunction, also known as cardiorenal disease. CorMedixs goal is to treat kidney disease by reducing the commonly associated cardiovascular and metabolic complications. The Companys therapeutic candidates for cardiorenal disease may be small molecules, biologicals, devices and/or diagnostics (tests) that enable therapy. Its product pipeline includes: CRMD001, a unique formulation Deferiprone which is in development to prevent Contrast-Induced Acute Kidney Injury and to slow progression of Chronic Kidney Disease; CRMD002, a diagnostic test for urinary labile iron; CRMD003 (Neutrolin?, an antimicrobial/anticoagulant solution) is in development to prevent Catheter Related Bloodstream Infection; CRMD004, a pressure sensitive gel which has many uses, including extending the benefits of Neutrolin?. CorMedix Inc. is based in Summit, New Jersey.